Folate receptor α (FRα) came into focus as an anticancer target many decades after the
successful development of drugs targeting intracellular folate metabolism, such as …

Over the past 5 years, improvements in the design of antibody–drug conjugates (ADCs)
have enabled major advances that have reshaped the treatment of several advanced-stage …

PURPOSE Single-agent chemotherapies have limited activity and considerable toxicity in
patients with platinum-resistant epithelial ovarian cancer (PROC). Mirvetuximab …

Antibody–drug conjugates (ADCs) are a relatively new class of anticancer agents designed
to merge the selectivity of monoclonal antibodies with cell killing properties of …

Simple Summary Antibody-drug conjugates (ADC) are a rapidly expanding class of anti-
cancer drugs, with twelve agents in current clinical use. Despite recent successes, many …

Antibody-drug conjugates (ADCs) are complex engineered therapeutics consisting of
monoclonal antibodies, directed toward tumor-associated antigens, to which highly potent …

Mirvetuximab soravtansine (mirvetuximab soravtansine-gynx; Elahere™) is an antibody-
drug conjugate (ADC), which is comprised of a folate receptor α (FRα) directed antibody …

As one of the major therapeutic options for cancer treatment, chemotherapy has limited
selectivity against cancer cells. Consequently, this therapeutic strategy offers a small …

Antibody-drug conjugates (ADCs) are cancer therapeutic agents comprised of an antibody,
a linker and a small-molecule payload. ADCs use the specificity of the antibody to target the …

The concept of exploiting the specific binding properties of monoclonal antibodies as a
mechanism for selective delivery of cytotoxic agents to tumor cells is an attractive solution to …